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Abstracts / Biol Blood Marrow Transplant 21 (2015) S147eS170 S159GVHD prophylaxis consisted of the continuous infusion of
tacrolimus, 1 mg/kg/day of methylprednisolone, and 15 mg/
kg/day ofMMF. PBSC containing 1.78-8.46 * 10e6/kg of CD34+
cells were transplanted in all cases.
Findings & Interpretation: Granulocyte engraftment was
achieved on days 9-11 in all cases. Complete spousal chi-
merism in PB was conﬁrmed on days 3-13 by STR-PCR.
Acute GVHD was controllable except in the rejection case,
who died of grade IV GVHD on day 39. All ﬁve relapse
cases achieved complete remission once, and three could
be discharged. One patient died of VOD/SOS on day 62, and
one patient was transferred to her local hospital. The
remaining four patients excluding GVHD and VOD/SOS
cases ﬁnally developed disease relapse (in BM 2, CNS 2) on
days 106-334, and died as a direct result on days 152-548.
Discussion & Implications: Since these cases are refractory
and they received their third SCT, we cannot refer to the
GVL effect, and GVHD would be acceptable in spousal SCT.
The immune recovery remains to be elucidated over a
long-term follow-up.192
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In a pilot study, we carried out Haploidentical trans-
plantation for 10 patients with severe aplastic anemia (SAA)
using peripheral blood stem cell (PBSC) graft and post-
transplantation cyclophosphamide (PTCY). The conditioning
comprised of Fludarabine 150 mg/m2, CY 30 mg/kg, horse
ATG 45 mg/kg and Melphalan 120 mg/m2, followed by PTCY
50 mg /kg on D+3, +4 and cyclosporine and mycophenolate
from D + 5. Prompt engraftment was followed by early
alloreactivity, resulting in transplant-relatedmortality in 4 of
the ﬁrst 5 patients, all with NK Ligandmismatched donors. In
the subsequent 5 patients, Sirolimus was introduced from
Day -7 to maintain a trough level of 8-14 ng/ml on the day of
transplant and was continued for 12months post-transplant,
with a reduced trough level for cyclosporine. All 5 patients
had prompt engraftment with 78-100% donor chimerism
and mild chronic GVHD in one patient only. The only sig-
niﬁcant toxicity observed in these patients was Sirolimus
associated acneform lesions. Analysis of Regulatory T cells at
45 days posttransplant was 0.09  0.13% in the ﬁrst 3/5 pa-
tients compared to 2.6  0.77% in those receiving Sirolimus
(p¼0.001). Our study demonstrates that NK cell ligand mis-
matched donors are associated with early alloreactivity
following Haploidentical PBSC transplantation for SAA but
addition of Sirolimus to PTCY improves tolerance and out-
come.193
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Background: Almost 1% of the Japanese population has HLA-
homozygous haplotypes (the same HLA haplotypes). An HLA
mismatch between patients with HLA-homozygous haplo-
types and their children or parents is absent in the graft-
versus-host (GVH) direction. Hematopoietic stem cell
transplantation (SCT) from a haploidentical donor with HLA
mismatch only in the host-versus-graft (HVG) direction was
feasible using standard GVHD prophylaxis (Ikegame K, et al.
IJH 2012). However, this should be validated in a larger
cohort.
Methods: We analyzed 229 patients with hematologic ma-
lignancies who had homozygous HLA-A, -B, and -DR antigens
and received their ﬁrst allogeneic SCT from a related donor
without an HLA mismatch in the GVH direction between
1998 and 2012 in Japan. In total, 155 patients received SCT
from an HLA-matched related donor (homo-to-homo SCT)
and 74 received SCT from a haploidentical donor with HLA
mismatch only in the HVG direction (hetero-to-homo SCT).
High-risk disease and the use of tacrolimus were more
frequently observed in the hetero-to-homo SCT group. The
number of HLA mismatches in the HVG direction was 1 in 16
patients, 2 in 27 patients, and 3 in 31 patients. The impact of
hetero-to-homo versus homo-to-homo SCT was analyzed
after adjusting for transplant year, age, and other signiﬁcant
variables.
Results: There was no signiﬁcant difference in the cumu-
lative incidence of neutrophil engraftment and severe
acute GVHD between the hetero-to-homo and homo-to-
homo SCT groups (neutrophil engraftment at 50 days, 91%
vs. 95%; adjusted hazard ratio (aHR) 1.05, P ¼ 0.768; se-
vere acute GVHD at 100 days, 10% vs. 5%; aHR 1.68, P ¼
0.320). Non-relapse mortality was signiﬁcantly higher in
the hetero-to-homo SCT group than in the homo-to-homo
SCT group (26% vs. 10% at 5 years; aHR 2.42, P ¼ 0.013),
whereas there was no signiﬁcant difference in the relapse
rate. This resulted in non-signiﬁcant lower overall survival
in the hetero-to-homo SCT group (35% vs. 57% at 5 years;
aHR 1.41, P ¼ 0.083).
Conclusions: Hetero-to-homo SCT is usually considered
only when transplantation should be performed immedi-
ately for high-risk disease. Therefore, differences in patient
background between the homo-to-homo and hetero-to-
homo SCT groups may have biased the comparison. How-
ever, it should be noted that there was no signiﬁcant
difference in neutrophil engraftment as well as severe acute
GVHD. Although non-relapse mortality and overall mortal-
ity rates were higher in the hetero-to-homo SCT group than
Abstracts / Biol Blood Marrow Transplant 21 (2015) S147eS170S160in the homo-to-homo SCT group, hetero-to-homo SCT may
be considered when immediate transplantation is required
but an appropriate alternative donor is not available oth-
erwise.194
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In the present retrospective study we analyzed 382 patients
undergoing HSCT between 1995 and 2011. Of these 115 pa-
tients received an HLA-CmmHSCTand 266 received an HLA-
C matched graft. Only patients with malignant disease were
included in the analysis with no signiﬁcant differences be-
tween patients with HLA-C matched or mm donors. Median
age was 42 (<1-68) versus 41 (<1-65) years in the matched
and mm groups respectively. Early/late disease was 119/147
and 51/64, respectively (ns). Reduced intensity conditioning
was given to 100 patients (38%) among HLA-C matched pa-
tients compared to 42 (37%) in the HLA-C mm group. Mye-
loablative conditioning was similar in both groups. Female
donor to male recipient was given to 20 (8%) in the matched
group versus 19 (17%) in the mm group. Bone marrow was
used as stem cell source in 74 (28%) patients in the HLA-C
matched group compared to 45 (39%) in the mm group (ns).
The remaining patients received PBSC in each group. Median
CD34 cell dose (x106/kg) was 7.2 (0.2-56.4) versus 7.1 (0.3-
28.7), respectively. GVHD prophylaxis consisted of CsA +MTX
in 84% versus 85% of the patients in each group. ATG was
given to all patients before HSCT.
In the present material graft failure (GF) occurred in 9
(3.4%) in HLA-C matched group compared to 7 (6.1%) in the
mm group (ns). In multivariate analysis for GF, major AB0
mismatch (p¼0.03), RIC (p¼0.01) and female donor to male
recipient (p¼0.002) were signiﬁcant risk factors. HLA-C mm
was not found to be signiﬁcant (p¼0.71). Neither had HLA-C
mm any impact onmortality. Signiﬁcant factors associated to
mortality in multivariate analysis were: disease stage
(p<0.001), year of HSCT (p¼0.015) and donor age (p<0.001).
For acute GVHD grades II-IV CsA+MTX (p<0.001) and RIC
(p<0.001) decreased the risk whereas the use of PBSC
(p¼0.016) increased the risk. HLA-C matched patients
compared to HLA-C mm showed no statistical difference
regarding TRM, RFS, mortality, acute GVHD grades II-IV and
relapse incidence. We also analyzed MFI for all HLA-C alleles
which showed no signiﬁcant correlation to outcome.
In conclusion, in the present study we ﬁnd no negative
impact of HLA-C mismatch on outcome after HSCT.195
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Background: Patients with graft failure or disease relapse
following allogeneic hematopoietic cell transplant (HCT)
have <10% survival with no intervention. Second HCT in this
situation is becoming more common. Advantages of cordblood (UCB) in this setting include prompt availability of
donor cells, no donor risk during cell procurement, and po-
tential of enhancing the graft versus leukemia effect through
use of highly mismatched grafts. We sought to determine the
feasibility of second allogeneic transplant with UCB.
Methods: Twenty-three patients median age 33 yrs (range
4-69 yrs) received a CB transplant (CBT) as a second alloge-
neic HCT at the Fred Hutchinson Cancer Research Center
between 2006e2013. Indication for second allograft were
relapse (n ¼ 19), graft failure (n ¼ 3) and donor derived MDS
(n ¼ 1). Median time between transplants was 505 days
(range, 55-3515). At the time of second HCT, 19 patients were
in CR and 4 patients had persistent disease. For their second
transplant, 10 patients received reduced intensity condi-
tioning (RIC) with ﬂudarabine (Flu) 200mg/m2, cyclophos-
phamide (Cy) 50 mg/kg and 200-400 cGy TBI, 2 patients
received myeloablative (MAC) conditioning with Flu 75mg/
m2, Cy 120mg/kg and 1200-1320cGy TBI (n ¼ 2), and 11
patients received “midi” conditioning with treosulfan 42mg/
kg, Flu 150-200mg/m2 and 200 cGy TBI. All patients received
GVHD prophylaxis with cyclosporine and mycophenolate
mofeteil. Twenty of the 23 patients received a double CBT
with a median TNC of 4.8 x 107 cells/kg and a median CD34+
of 2.2 x 105 cells/kg. Twelve patients received at least one 4/6
graft; 9 patients received at least one 5/6 graft.
Results:Median time to engraftment was 22 days (range day
6-49) among 21 evaluable patients; 2 patients died prior to
engraftment. Median time to platelet engraftment was 55
days (range 23-83). Day +28 CD3+ chimerism was 100%
second transplant donor in 16 of 19 evaluable patients, and
100% ﬁrst donor in 2. One patient was mixed between ﬁrst
(22%) and second donor (78%). Death prior to Day 100 was
seen in 5 patients (infection/organ failure (n ¼ 3), encepha-
lopathy (n ¼ 1), and relapse (n ¼ 1). Acute grade II-IV and III-
IV GVHD was diagnosed in 18 of 21 and 6 of 21 evaluable
patients respectively, and 9 of 16 evaluable patients devel-
oped chronic GVHD (6 mild, 2 moderate, 1 severe). Disease
free survival, treatment related mortality, and relapse at 2
years was 40%, 33%, and 35% respectively. Patients receiving
MAC/midi vs RIC conditioning experienced a 2-year DFS of 46
vs 15% (p ¼ 0.02) and relapse rate of 26 vs 45% (p ¼ 0.20).
Conclusions: Our results demonstrate quite favorable out-
comes in patients undergoing CBTas a second allogeneic HCT,
with all evaluable patients engrafting and full donor chime-
rism achieved in 16 of 19 patients byDay +28. The use of CB as
the stem cell source is particularly attractive in this setting as
it eliminates the need to put a conventional donor at risk.196
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Human leukocyte antigen (HLA)-mismatced/haploidentical
stem cell transplantation (SCT) is a known risk factor for
human herpesvirus 6 (HHV-6) infection. High plasma HHV-6
DNA loads in peripheral blood have been associated with the
development of HHV-6-associated encephalitis. However,
previous results have been obtained in patients who under-
went HLA-matched SCT or combined populations, including
a small number of HLA-mismatched SCTs.
